Smart device maker Aradigm aims to seek more market funds if bid for development partnership fails
This article was originally published in Clinica
Aradigm, a US developer of hand-held smart devices for pulmonary delivery of therapeutics and imaging agents, may return to the market early next year for a further tranche of investor funds, according to its president and CEO, Richard Thompson.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.